All Cancer articles – Page 22
-
NewsNew molecular imaging technique improves breast cancer diagnostics
Low-dose positron emission mammography (PEM) has a high sensitivity for detecting cancer and reduces the likelihood of false positives.
-
NewsLung adenocarcinoma: metabolic reprogramming of macrophages
Disrupting the mechanism that EGFR-driven lung adenocarcinoma uses to alter macrophages’ lipid metabolism could inspire new treatments.
-
ArticleInvestigating the intratumoural microbiome in young-onset CRC patients
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
-
NewsIntegrin αV and β5 partner to drive cancer cell growth
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
-
NewsReducing drug resistance in acute myeloid leukaemia patients
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
-
NewsOrganoid drug testing predicts bowel cancer treatment response
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
-
ArticleThe great prostate debate: innovations in prostate cancer screening
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its ...
-
NewsHow the DA subtype of Wilms tumour resists chemotherapy
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
-
WhitepaperApplication Note: Understanding The Multiplex Imaging Landscape
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
-
NewsAugmenting cancer immunogenicity through MHC class I
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
-
NewsImproving cancer treatment by exploiting mtDNA mutations
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
-
News
Novel prediction tool accurately determines disease stage
A new learning-based framework enables patients and caregivers to predict the timing of any of the five clinical groups of AD development.
-
News
Targeting Ku70 could improve bowel cancer treatment
The Ku70 protein prevents cancer cells from becoming more aggressive and metastasising. It could also be used as an immune biomarker.
-
ArticleTherapeutic peptide developed for triple-negative breast cancer
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
-
NewsNew immunological pathway to treat bone tumours
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
-
NewsThe potential of PD-L2 inhibitors for cancer treatment
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
-
News
PLK4 inhibition: a new therapeutic for AML
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
-
NewsAdvancing personalised medicine with a cholangiocarcinoma model
A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.
-
NewsKnockdown of FAM3C inhibits breast cancer tumour growth
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
-
News
New algorithm can predict when cancer will resist chemotherapy
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.